Published in Cancer Weekly, December 3rd, 2002
These patents cover antibodies that specifically recognize CEA, one of the most widely used markers for colorectal and other cancers. Under the license agreement, Medix Biochemica agreed to pay an up-front payment and royalties, as well as back-royalties and interest to Immunomedics for prior use of the patented technologies.
As a licensee, Medix Biochemica will now be permitted to use the patents worldwide for in vitro immunodiagnostics used for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.